

DLL3

Catalog # PVGS1830

Product Information

Primary Accession Species	Q9NYJ7-1 Human
Sequence	Val311-Ala479
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Immobilized DLL3 Domain (311-479), His&Avi, Human (Cat.No.: Z03951) at 1 μ g/ml (100 μ l/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag
Expression System	HEK293
Theoretical Molecular Weight	21.20 kDa
Formulation	Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4).
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.
--------------------------	---

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.